Featured Press Releases

Immorta Bio Reports Successful Lung Cancer Growth Inhibition by Senolytic Immunotherapy SenoVax™

Immorta Bio Reports Successful Lung Cancer Growth Inhibition by Senolytic Immunotherapy SenoVax™

Tentarix Biotherapeutics announces appointment of Andrew D. Kidd, MD, CFA, as CEO

Tentarix Biotherapeutics announces appointment of Andrew D. Kidd, MD, CFA, as CEO

  • 23 Apr 2024

Tentarix Biotherapeutics announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

Connected Pill Box Unveiled by Hello Heart to Radically Improve Medication Adherence

Connected Pill Box Unveiled by Hello Heart to Radically Improve Medication Adherence

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Gene Therapy Assets of Klotho Available

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Gene Therapy Assets of Klotho Available

Samsung Biologics introduces

Samsung Biologics introduces 'Samsung Organoids'—a novel drug screening service utilizing lab-grown human organ models to enhance oncology research

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

  • CollPlant
  • 24 Feb 2026
With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

  • Bruker Corporation
  • 24 Feb 2026
SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

  • Clarity Pharmaceuticals
  • 23 Feb 2026
PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

  • PureTech Health plc
  • 20 Feb 2026
ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

  • Merck & Co., Inc.
  • 19 Feb 2026
Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.